Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an update.
Botanix Pharmaceuticals has opened registration for an investor webinar to be hosted by Executive Chairman Vince Ippolito, CEO Dr Howie McKibbon and U.S. CFO Chris Lesovitz. The session, scheduled for 29 April 2026, will provide detailed commentary on the company’s Quarterly Activity Report, 4C cash flow update and progress of its flagship hyperhidrosis treatment Sofdra, giving investors greater visibility into its commercial trajectory and financial performance.
The webinar is positioned as an opportunity for stakeholders to hear directly from the leadership team on operational developments and the commercial rollout of Sofdra. By engaging investors through this briefing, Botanix aims to reinforce market confidence, clarify its strategic direction in dermatology and highlight the potential impact of Sofdra’s FDA-approved status on future growth.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix that focuses on treatments for skin conditions. The company has received U.S. FDA approval for Sofdra, a novel new chemical entity for primary axillary hyperhidrosis, offering a safe and effective option to patients who have had limited therapies for this socially challenging disorder.
Average Trading Volume: 15,652,456
Technical Sentiment Signal: Sell
Current Market Cap: A$94.92M
For an in-depth examination of BOT stock, go to TipRanks’ Overview page.